×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HROW – harrow, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HROW
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
07:00 am
hrow
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
Medium
Report
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
11/20
07:00 am
hrow
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Medium
Report
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
11/15
07:00 am
hrow
Harrow Announces Participation in Upcoming Investor Conferences
Medium
Report
Harrow Announces Participation in Upcoming Investor Conferences
11/13
04:34 pm
hrow
Harrow Announces Third Quarter 2024 Financial Results
High
Report
Harrow Announces Third Quarter 2024 Financial Results
11/13
07:00 am
hrow
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
Medium
Report
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
11/12
07:00 am
hrow
Harrow Announces Market Access Wins for VEVYE®
Medium
Report
Harrow Announces Market Access Wins for VEVYE®
11/7
07:00 am
hrow
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
Medium
Report
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
10/31
07:00 am
hrow
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
Low
Report
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:24 am
hrow
Form 10-Q HARROW, INC. For: Sep 30
High
Report
Form 10-Q HARROW, INC. For: Sep 30
11/14
06:16 am
hrow
Form 8-K HARROW, INC. For: Nov 13
High
Report
Form 8-K HARROW, INC. For: Nov 13
10/28
07:01 am
hrow
Form 8-K HARROW, INC. For: Oct 25
Medium
Report
Form 8-K HARROW, INC. For: Oct 25
10/8
06:42 am
hrow
Form SC 13G/A HARROW, INC. Filed by: Ophir Asset Management Pty Ltd
Low
Report
Form SC 13G/A HARROW, INC. Filed by: Ophir Asset Management Pty Ltd
9/13
05:27 pm
hrow
Form 4 HARROW, INC. For: Sep 11 Filed by: SAHAREK JOHN P.
Medium
Report
Form 4 HARROW, INC. For: Sep 11 Filed by: SAHAREK JOHN P.
9/9
07:31 am
hrow
Form 8-K HARROW, INC. For: Sep 09
Low
Report
Form 8-K HARROW, INC. For: Sep 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.450 ZacksConsensus -0.020 ActVsEst (0.430) - Miss
23.5%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
TOP News Decliners
8/14
Form 4 HARROW HEALTH, INC. For: Aug 12 Filed by: Kammer Robert J
-24.8%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: